Company
Genuity Science (acquired)
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
What it was
Genuity Science (formerly WuXi NextCODE Health, formerly NextCODE Health) was an Iceland/Boston-based genomics company that pioneered analysis of population-scale genomic data for drug-target discovery and patient stratification.
It was acquired by HealthVerity in 2023, ending its independent existence.
Why it matters historically
Genuity (and its predecessor deCODE genetics, separately) demonstrated that:
- Population-scale genomic + phenotypic data can identify novel drug-target genes through statistical association.
- Founder populations (Iceland, Finland) provide unique power for rare- variant discovery.
- Genomics + EHR integration accelerates pharmaceutical drug development.
Influence on longevity research
The general approach — large-scale genomic + multi-omic + phenotypic integration to find aging modifiers — is now standard at Calico, BioAge, and many others. Genuity was an early-stage demonstration of the model.